SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Esquire shareholders voted on June 23, 2026 to approve the issuance of common stock to Signature Bancorporation shareholders pursuant to a merger agreement, with 6,568,618 votes in favor, 9,444 against, and 7,992 abstentions.
View raw filing on EDGAR →Esquire announced receipt of all required stockholder and regulatory approvals for the merger of Signature Bancorporation with and into Esquire, with a final exchange ratio of 2.671 Esquire shares per Signature share and closing anticipated in Q3 2026.
View raw filing on EDGAR →This exhibit announces the poll results of NIO Inc.'s 2026 Annual General Meeting held on June 24, 2026, disclosing that "proposed resolutions set out in our notice of the annual general meeting dated May 22, 2026 were taken by poll and duly passed." This is a direct disclosure of shareholder vote results at an annual meeting, matching the shareholder_vote_results event type. The announcement is material as it confirms shareholder approval of board-level governance matters at the annual meeting.
View raw filing on EDGAR →Philip Whitehead, President and CEO of the EMEA&APAC business, is stepping away from his role due to a medical condition. Although described as "temporary," this constitutes a departure of a senior officer from an active executive position. The appointment of Simon Kerry as interim replacement is secondary to the principal event—Whitehead's departure. The materiality reflects the significance of a regional CEO stepping away, even if temporarily.
View raw filing on EDGAR →The 6-K discloses the Board's approval on June 22, 2026, of Dr. Cheng Chen's appointment as an independent director, effective immediately. Dr. Chen will also serve on the audit committee, compensation committee, and corporate governance and nominating committee. This is a clear executive/director appointment that would affect a reasonable investor's assessment of the company's governance and board composition.
View raw filing on EDGAR →The Board authorized termination of the Weyco Group, Inc. Pension Plan effective August 31, 2026, with the plan currently overfunded as of December 31, 2025, requiring no additional cash contributions upon termination. This is a material financial event involving the wind-down of a significant employee benefit obligation affecting approximately 400 participants, but it does not fit the specific categories of debt issuance, dividend distribution, material impairment, or restatement—making it a financial event that falls outside named categories.
View raw filing on EDGAR →The 6-K body announces completion of a financing bond issuance by Turkcell of TRY 500,000,000 (approximately USD 15+ million equivalent) with a 93-day maturity and 40.25% annual interest rate. The announcement details the book building completion, settlement date (June 24, 2026), and full terms of the debt security, constituting a material creation of a direct financial obligation under Item 2.03 equivalent disclosure.
View raw filing on EDGAR →The 6-K body announces completion of a financing bond issuance by Turkcell of TRY 500,000,000 (approximately USD 15+ million equivalent) with a 93-day maturity and 40.25% annual interest rate. The announcement details the book building completion, settlement date (June 24, 2026), and full terms of the debt instrument, constituting a material creation of a direct financial obligation under Item 2.03 equivalent disclosure.
View raw filing on EDGAR →The filing discloses entry into material definitive agreements in connection with the issuance of asset-backed securities (Notes) by Ford Credit Auto Owner Trust 2026-B. This represents the creation of a new direct financial obligation through securitization, which is a form of debt issuance. The prospectus dated June 16, 2026 was filed under Rule 424(b)(2), confirming a registered securities offering.
View raw filing on EDGAR →BBVA executed a partial share capital reduction by canceling 52,800,888 treasury shares (par value €25.9 million) acquired through a share repurchase program authorized by the March 20, 2026 shareholder meeting. While technically a capital reduction rather than a dividend, this represents a return of capital to shareholders through share cancellation—a form of capital distribution. The materiality lies in the scale (52.8 million shares canceled) and the formal shareholder authorization, making it a material capital event affecting the share structure and shareholder equity.
View raw filing on EDGAR →The 6-K announces the redemption and coupon payment of a financing bond (ISIN TRFTCEL62621) with a nominal amount of TRY 530,000,000 and a 41% annual interest rate, completed on June 24, 2026. While technically a redemption (debt retirement) rather than issuance, this represents a material debt event involving the creation and maturity of a direct financial obligation. The high interest rate and substantial nominal amount indicate materiality to investors assessing the registrant's capital structure and financing costs.
View raw filing on EDGAR →The 6-K announces the redemption and coupon payment of a financing bond (ISIN TRFTCEL62613) with a nominal amount of TRY 500,000,000 and a 40.25% annual interest rate, completed on June 24, 2026. While technically a redemption (repayment) rather than issuance, this disclosure relates to a material direct financial obligation and its settlement. The high interest rate and substantial principal amount (TRY 500M) indicate materiality to investors assessing the registrant's capital structure and debt management.
View raw filing on EDGAR →Passage Bio entered into a definitive Agreement and Plan of Merger with Remix Therapeutics on June 24, 2026, whereby Passage Bio's subsidiary will merge with Remix, with Remix continuing as a wholly owned subsidiary and the combined company operating as Remix Therapeutics. The all-stock transaction values Remix at approximately $226 million and Passage Bio at approximately $20 million, with Passage Bio shareholders expected to own ~7% of the combined entity post-closing; the transaction includes concurrent $100 million private placement financing and is expected to close in Q4 2026 subject to customary closing conditions including stockholder approval.
View raw filing on EDGAR →This Item 7.01 disclosure furnishes a shareholder letter from CEO Michael Mo outlining KULR's strategic vision, platform development, and business outlook across five end markets (space & defense, low altitude economy, AI data center backup, energy as a service, and robotics). While the letter discusses operational strategy and market positioning rather than a discrete operational event, it constitutes a material strategic communication that would affect a reasonable investor's understanding of the company's direction and competitive positioning in the physical AI infrastructure space.
View raw filing on EDGAR →The filing discloses the dismissal of Wipfli LLP as the Company's independent registered public accounting firm effective June 22, 2026, and the appointment of Plante & Moran, PLLC as the new auditor. This is a classic auditor change under Item 4.01. While the filing notes no disagreements or reportable events (except a previously disclosed and remediated material weakness in internal controls), the change itself is material to investors as it affects the registrant's financial reporting oversight and audit continuity.
View raw filing on EDGAR →uniQure entered into an underwriting agreement on June 23, 2026 for a registered public offering of 4,945,055 ordinary shares at $45.50 per share, with underwriters granted a 30-day option to purchase an additional 741,758 shares (exercised in full on June 24, 2026), expected to generate approximately $225 million in gross proceeds and materially dilute existing shareholders.
View raw filing on EDGAR →Colony Bankcorp entered into a definitive Agreement and Plan of Merger with First Reliance Bancshares on June 24, 2026, whereby FSRL will merge into Colony in a combined stock-and-cash transaction valued at approximately $163 million ($19.75 per share in cash or 0.94 shares of Colony stock, ~20% cash and 80% stock). The transaction creates a combined entity with approximately $5 billion in assets and has been unanimously approved by both boards, subject to shareholder approval and regulatory clearance, with expected closing in Q4 2026.
View raw filing on EDGAR →The filing discloses the consummation of Yorkville International Capital Corp.'s IPO on June 17, 2026, generating $230 million in gross proceeds from the sale of 23 million units at $10.00 per unit, plus a concurrent private placement of 6.3 million warrants for $6.3 million. While this is clearly a material capital-raising event affecting a reasonable investor's assessment of the registrant, it does not fit neatly into the standard 8-K taxonomy. The event is neither a traditional earnings release, M&A activity, debt issuance, nor dilutive equity issuance in the conventional sense (the IPO itself is the primary capital event, not a secondary offering). The company is a SPAC with no operating business, making traditional financial event categories inapplicable. The domain is clearly financial/capital-related, but no specific category captures an IPO consummation disclosure.
View raw filing on EDGAR →The disclosure centers on Consolidated Water's entry into a new 25-year water utility license with the Cayman Islands regulator (OfReg), effective August 1, 2026. While this is a material definitive agreement under Item 1.01, it is fundamentally an operational and regulatory milestone rather than a traditional M&A transaction, debt issuance, or other specifically-named event type. The filing explicitly notes that the new license "establishes a long-term regulatory framework" following years of negotiation, and the Company's pro forma estimates indicate the new rate structure will reduce revenues by approximately $2.1–$2.6 million annually—a material impact on the registrant's core business operations and cash flows.
View raw filing on EDGAR →Definium entered into an underwriting agreement on June 23, 2026 for a public offering of 20,588,236 common shares at $34.00 per share, with underwriters exercising their full option for an additional 3,088,235 shares, generating approximately $805 million in gross proceeds. This registered public offering will dilute existing shareholders materially.
View raw filing on EDGAR →Spring Valley Acquisition Corp. III issued an unsecured promissory note in the principal amount of up to $1,500,000 to its sponsor on June 23, 2026. This is a creation of a direct financial obligation under Item 2.03, constituting a debt issuance. The note is material as it represents a significant financing arrangement for a SPAC, even though it is unsecured and non-interest-bearing, and includes a conversion feature into warrants upon the company's initial business combination.
View raw filing on EDGAR →This is a comprehensive technical report on the Gaocheng Silver-Lead-Zinc Project prepared by SRK Consulting for Silvercorp Metals Inc., effective December 31, 2025. The report covers mineral resource and reserve estimates, mining methods, processing, environmental permitting, capital and operating costs, and economic analysis. While technical reports are standard industry practice for mining operations, this document discloses material operational and financial information about the project's reserves, resources, and economic viability that would be relevant to investors assessing the registrant's asset base and future production capacity. It does not fit neatly into periodic financial reporting (which would be a 10-K or 10-Q equivalent) but rather represents a detailed operational and technical assessment of a material mining asset.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of RH's annual shareholder meeting held on June 18, 2026. The filing presents voting results for four proposals: election of three Class II directors (Hilary Krane, Katie Mitic, Ali Rowghani), advisory approval of named executive officer compensation, frequency of Say-on-Pay votes (approved for annual frequency), and ratification of PricewaterhouseCoopers LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder governance event.
View raw filing on EDGAR →The filing discloses that Femasys has regained compliance with Nasdaq Listing Rule 5550(a)(2) following a minimum bid price deficiency notice issued on July 16, 2025. While the company has now cured the deficiency through a 1-for-20 reverse stock split completed June 5, 2026, the core event is the resolution of a delisting risk that previously threatened the company's continued listing on Nasdaq. This is material to investors as it directly affects the company's ability to remain publicly traded.
View raw filing on EDGAR →Ionis announced FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia on June 24, 2026, based on positive Phase 3 CORE and CORE2 trial results. This represents the company's first independent commercial launch in a prevalent disease and a significant regulatory milestone for its novel RNA-targeted therapy platform.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from Femasys Inc.'s Annual Meeting of Stockholders held on June 24, 2026. The filing presents detailed vote tallies for two proposals: (1) election of two Class II directors (Charles Larsen and Kenneth Eichenbaum) and (2) ratification of KPMG LLP as the independent registered accounting firm. Both proposals passed with substantial majorities. This is a routine but material shareholder vote result disclosure required by Item 5.07 of Form 8-K.
View raw filing on EDGAR →Global Ship Lease announced entry into newbuilding contracts for five containerships with an aggregate purchase price of approximately $413 million, scheduled for delivery within 2029 and contracted on multi-year charters. This represents a material capital commitment and acquisition of assets that would affect a reasonable investor's assessment of the company's fleet composition, cash generation capacity, and strategic direction. The announcement explicitly references these as additions to the company's "overall newbuilding orderbook to 15 ships" expected to generate over $1.0 billion in Adjusted EBITDA.
View raw filing on EDGAR →Teradata entered into a new $400 million unsecured revolving credit facility with Bank of America on June 24, 2026, replacing a prior 2022 credit agreement. The new facility has a five-year term with customary covenants and represents a material refinancing of the company's capital structure and liquidity position.
View raw filing on EDGAR →CarMax held its Annual Meeting of Shareholders on June 23, 2026, with voting results including election of directors, ratification of KPMG LLP as auditors, approval of the executive compensation advisory resolution, and approval of amendments to the 2002 Stock Incentive Plan.
View raw filing on EDGAR →NOVAGOLD issued a press release on June 24, 2026 announcing financial results for the fiscal quarter ended May 31, 2026, disclosing net loss of ($25.5) million, earnings per share of ($0.06), cash position of $370.2 million, and operational cash expenditures of $22.7 million. The filing explicitly states "Details of the financial results for the quarter ended May 31, 2026 are presented in the consolidated financial statements and quarterly report on Form 10-Q filed on June 24, 2026," confirming this is a quarterly earnings disclosure under Item 2.02.
View raw filing on EDGAR →The exhibit discloses results of an annual and special meeting of shareholders held on June 23, 2026, including voting outcomes on four resolutions: election of seven directors (Resolution #1), re-appointment of PricewaterhouseCoopers LLP as auditor (Resolution #2), approval of registered office relocation from Québec to Ontario (Resolution #3), and approval of a name change to "Osisko Gold Group Inc." (Resolution #4). The press release presents detailed vote tallies and percentages for each resolution, which is the core disclosure required under Item 5.07 of Form 8-K (and analogous 6-K disclosure). The company also granted 247,129 deferred share units to independent directors as part of annual compensation review, which is ancillary to the shareholder vote disclosure.
View raw filing on EDGAR →The exhibit discloses voting results from Taseko's 2026 Annual General Meeting held June 24, 2026, including shareholder approval of a name change to Trekor Metals Limited (effective June 25, 2026), director elections, and amendments to the deferred share unit plan. The disclosure of specific vote percentages for each director nominee and approval of the name change constitutes a shareholder_vote_results event. The name change is material as it affects the company's identity and trading information across multiple exchanges (TSX, NYSE American, LSE).
View raw filing on EDGAR →MIND CTI Ltd. received a Nasdaq letter on June 23, 2026 indicating non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)) requiring a minimum of $1 per share. The company has 180 calendar days until December 21, 2026 to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status and investor assessment.
View raw filing on EDGAR →InMode received an unsolicited merger proposal from MN Business Strategy (a group including co-founder and CEO Moshe Mizrahy) to acquire all outstanding shares not already owned by the bidder at $16.20 per share in cash. The Board has formed a special committee to evaluate the proposal. This is a material M&A activity disclosure under Item 1.01 (entry into a material acquisition or change of control), as it involves a potential merger that would materially affect the company's structure and shareholder interests.
View raw filing on EDGAR →This is a disclosure of shareholder vote results from Nomura Holdings' 122nd Annual General Meeting held on June 23, 2026. The exhibit reports the voting outcomes for the appointment of 11 directors (Koji Nagai, Kentaro Okuda, Yutaka Nakajima, Shoji Ogawa, Victor Chu, Patricia Mosser, Takahisa Takahara, Miyuki Ishiguro, Masahiro Ishizuka, Taku Oshima, and Nellie Liang), with detailed vote counts and approval ratios for each nominee. All 11 director appointments were approved. This is a material governance event affecting the composition of the board of a major financial institution.
View raw filing on EDGAR →Prologis announced an indicative all-share acquisition proposal for SEGRO plc on June 24, 2026, following a June 16 letter setting out terms for an all-stock transaction. Although SEGRO's board rejected the proposal on June 23, the announcement of a material acquisition attempt—coupled with Prologis' stated intention to potentially make a firm offer by July 22, 2026 under UK takeover rules—constitutes a disclosure of M&A activity that would materially affect investor assessment of both parties.
View raw filing on EDGAR →Bilibili announced authorization of a new $300 million share repurchase program by its board of directors, effective immediately for the next 24 months. This represents a material capital return commitment to shareholders.
View raw filing on EDGAR →CalciMedica entered into a First Amendment to its Loan and Security Agreement on June 23, 2026, materially modifying the terms of a $10,000,000 debt facility by extending the interest-only period and maturity date by one year, increasing the final payment fee by $200,000, and significantly expanding conversion rights from $1,000,000 to $3,000,000 of principal into common stock or pre-funded warrants.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from MapLight Therapeutics' 2026 annual meeting held on June 23, 2026. The filing reports voting outcomes for two proposals: (1) election of three directors (Martin Babler, Troy Cox, and George Pavlov), all of whom were elected, and (2) ratification of RSM US LLP as the independent auditor for fiscal year 2026, which passed with overwhelming support. This is a routine but material governance disclosure required under Item 5.07.
View raw filing on EDGAR →The filing discloses a material acquisition transaction: Emerald Holding, Inc. entered into an Agreement and Plan of Merger with Apollo-managed funds on May 9, 2026, with Merger Sub to merge into Emerald, making Emerald a wholly-owned subsidiary of Parent. The press release confirms the transaction is expected to close in the second half of 2026 and announces leadership changes (Paul Miller as CEO of the combined entity, Hervé Sedky transitioning to senior advisor), which are ancillary to the primary M&A event. This is a change of control transaction material to any reasonable investor.
View raw filing on EDGAR →This is a clear earnings release disclosing Paychex's financial results for the fourth quarter and full fiscal year 2026 ended May 31, 2026. The press release reports total revenue of $6.5 billion (17% growth), operating income of $2.5 billion (14% growth), and diluted EPS of $4.89 (7% growth) for the full year, along with detailed quarterly comparisons and forward guidance for fiscal 2027. The disclosure is furnished under Item 2.02 and attached as Exhibit 99.1, which is the standard format for earnings releases in 8-K filings.
View raw filing on EDGAR →Sanofi announced regulatory approval of Sarclisa (isatuximab) subcutaneous formulation in Japan for multiple myeloma treatment, representing the second global approval for this formulation and a significant commercial milestone for the company's oncology portfolio.
View raw filing on EDGAR →Sanofi announced the appointment of Paulo Fontoura as Executive Vice President, Global Head of Research & Development Pharma, effective September 1, 2026, with membership on the Executive Committee reporting to the CEO.
View raw filing on EDGAR →European Commission approved Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, representing a significant regulatory and commercial milestone for Sanofi's neurology pipeline.
View raw filing on EDGAR →Sanofi announced regulatory approval of Wayrilz (rilzabrutinib) in Japan for treating immune thrombocytopenia (ITP), based on successful LUNA 3 phase 3 clinical trial results, enabling market entry for this novel therapeutic.
View raw filing on EDGAR →Eli Lilly and Company, through subsidiary LDH XV Corporation, completed the acquisition of all issued and outstanding ordinary shares of Centessa Pharmaceuticals plc via a court-sanctioned scheme of arrangement under UK law on June 24, 2026, for $38.00 per share in cash plus contingent value rights of up to $9.00 per share, resulting in Centessa becoming a wholly owned subsidiary of Lilly and a complete change of control.
View raw filing on EDGAR →The filing discloses an ongoing private placement offering of up to $2.165 billion of common shares across multiple classes, with $534.084 million already raised as of May 31, 2026. This represents a substantial unregistered equity issuance that would dilute existing shareholders. While the filing also mentions dividend declarations and DRIP activity, the primary material event disclosed in Item 8.01 is the status and scale of the continuous private offering, which is a classic dilutive issuance event material to investors.
View raw filing on EDGAR →The Board of Trustees approved a material change to the Fund's 80% investment policy effective August 28, 2026, broadening the definition of eligible investments to include "income-producing investments" beyond traditional corporate debt, and expanding the types of instruments that may be counted toward the policy. This is a governance decision affecting the Fund's fundamental investment mandate and requires 60-day shareholder notice, making it material to investors' understanding of the Fund's strategy and operations.
View raw filing on EDGAR →The Board of Trustees approved a material change to the Fund's 80% investment policy effective August 28, 2026, broadening the definition of eligible investments to include income-producing investments beyond corporate debt obligations. This is a governance event—a board-approved policy amendment affecting the Fund's investment mandate—that would materially affect investor expectations about the Fund's portfolio composition and risk profile. While not a named governance category (such as an executive appointment or auditor change), it clearly falls within governance-related matters requiring board approval and shareholder notification.
View raw filing on EDGAR →The Board of Trustees approved a change to the Fund's 80% investment policy effective August 28, 2026, expanding the definition of eligible investments to include a broader range of income-producing instruments and fixed income securities. This is a material governance and policy amendment affecting the Fund's investment mandate and strategy, disclosed under Item 8.01 (Other Events). While not a named governance category (such as an executive appointment or auditor change), it represents a significant policy decision by the board that would affect investor expectations about the Fund's portfolio composition and risk profile.
View raw filing on EDGAR →